ZLAB – PDUFA

Importantly, this is NOT the only event for ZLAB, as through this entire week they are attending the Bay Helix East West Summit all week.  So they will have an audience to announce these results to.  This speaks to the Runup Traders and the Event Traders, and if the results are strong, in this special case, it could also be important to the Afterglow traders, because as of the 3rd quarter announcement, they had over 1 billion dollars in cash, so an offering doesn’t feel as imminent.

As announced with their 3rd Quarter Results, ZLAB has a PDUFA on Dec 14 for ”

• Potential FDA approval and commercial launch in the United States for adagrasib as the treatment for patients with NSCLC harboring the KRAS^G12C mutation who have received at least one prior systemic therapy; Prescription Drug User Free Act (PDUFA) target action date of December 14, 2022.”

Event PR: https://ir.zailaboratory.com/zh-hant/news-releases/news-release-details/zai-lab-announces-third-quarter-2022-financial-results-and?mobile=1